Latest Organophosphates Stories
CRANBURY, N.J., July 16 /PRNewswire-FirstCall/ -- Innophos Holdings, Inc. (Nasdaq: IPHS), a leading specialty phosphates producer in North America, today announced that it will host a live conference call on Tuesday, August 3, 2010 at 9:00 am ET to discuss its second quarter 2010 results. The press release detailing second quarter results will be issued on Monday, August 2, 2010 after market close. The conference call can be accessed by dialing 888-680-0893 (U.S.) or 617-213-4859...
LONDON, May 12 /PRNewswire/ -- Phosphates are excellent builders, but they are also plant nutrients; phosphate wastes entering surface water systems can result in excessive growth of algae. This eutrophication is a significant problem in a number of regions, particular in the developed countries. Although detergent phosphates are not normally the major source of phosphate contamination, they can be readily controlled by restricting use. Environmental concerns will continue as a strong...
CRANBURY, N.J., April 19 /PRNewswire-FirstCall/ -- Innophos Holdings, Inc. (Nasdaq: IPHS), a leading specialty phosphates producer in North America, today announced that it will host a live conference call on Tuesday, May 4, 2010 at 10:00 am ET to discuss its first quarter 2010 results. The press release detailing first quarter results will be issued on Monday, May 3, 2010 after market close. The conference call can be accessed by dialing 888-713-4217 (U.S.) or 617-213-4869...
Researchers report that they have discovered "“ and now know how to exploit "“ an unusual chemical reaction mechanism that allows malaria parasites and many disease-causing bacteria to survive. The research team, from the University of Illinois, also has developed the first potent inhibitor of this chemical reaction.The findings appear in the Proceedings of the National Academy of Sciences."There is an urgent need for new drugs to combat malaria and bacterial diseases such as...
ANNAPOLIS, Md., Dec. 7 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced Phase I clinical trial results for Protexia®, a pegylated recombinant version of human butyrylcholinesterase (rBChE), which has been shown to be effective in animal models in preventing toxicity from exposure to chemical nerve agents. The results were presented in an oral presentation on...
NEW YORK, Nov. 10 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Iron (III) Phosphate Dihydrate (CAS 13463-10-0) Market Research Report 2009 http://www.reportlinker.com/p0163691/Iron-(III)-Phosphate-Dihydrate-(CAS-13463-10-0)-Market-Research-Report-2009.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire The study 'Iron (III) Phosphate Dihydrate (CAS 13463-10-0) Market Research Report 2009' presents an...
Last Oregon Chemical Weapons Stockpile Campaign Begins HERMISTON, Ore., June 4 /PRNewswire-USNewswire/ -- Umatilla Chemical Depot (UMCD) storage workers began delivering HD mustard-filled bulk containers or "ton containers" to the Umatilla Chemical Agent Disposal Facility (UMCDF) at 10 a.m. this morning. This marks the official start of the last individual chemical munitions disposal campaign at the depot. "Our experienced crews are dedicated to safe and secure munitions movement and...
ANNAPOLIS, Md., Oct. 15 /PRNewswire-FirstCall/ -- PharmAthene, Inc. , a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the Consolidated Security, Disaster Assistance, and Continuing Appropriations Act, 2009, which includes the full-year FY 2009 appropriations for the Department of Defense (DoD), includes $1.6 million to support ongoing development of the Company's broad spectrum chemical nerve agent countermeasure,...
Cenomed BioSciences, a majority-owned subsidiary of Abraxis BioScience, and TorreyPines Therapeutics, a biopharmaceutical company, have signed an exclusive licensing agreement. Under the terms of the agreement, Cenomed acquired from TorreyPines Therapeutics the worldwide development rights to three compounds, phenserine, Posiphen and bisnorcymcerine, for chemical defense and counterterrorism defense. Cenomed intends to develop these compounds for potential use in preventing toxicity...
Excerpt from report by corporate-owned Russian news agency Interfax Kirov, 30 September: A regional commission for scrapping chemical weapons in Kirov Region has examined the readiness of the Maradykovskiy chemical weapons disposal site to launch its second phase in March 2009, the press centre of the regional government said on 30 September. The second stage facilities are equipped to scrap ammunition filled with the toxic substances sarin and soman. The remaining ammunition filled with...
